Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benvitimod cream plus IL-17 monoclonal antibody for refractory lower-leg plaque psoriasis lesions
ChiCTR2400085598Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tapinarof, secukinumab and ixekizumab in plaque psoriasis (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Psoriasis Area and Severity Index at week 16. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
tapinarofsecukinumabixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2400085598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085598.